- Company
- Shingrix presents a new paradigm for shingles prevention
- by Eo, Yun-Ho Dec 20, 2022 06:05am
- Korea GSK's herpes zoster vaccine "Shingrix" announced its official launch. GSK held a press conference at InterContinental Seoul COEX on the 15th to commemorate the launch of Shingrix, a shingles-prevention vaccine, in Korea. At the meeting, Yoon Kyung-young, an infectious medicine professor at Korea University Anam Hospital, introduced the
- Company
- Reimb for Revlimid as maintenance therapy near after 4 yrs
- by Eo, Yun-Ho Dec 19, 2022 04:35am
- After 4 long years of await, Revlimid as maintenance therapy is nearing reimbursement listing in Korea. According to industry sources, the agenda of reimbursing Revlimid as maintenance therapy that has passed deliberations by the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee in June will be delib
- Company
- Severe asthma treatment Fasenra seeks reimb in KOR
- by Eo, Yun-Ho Dec 19, 2022 04:34am
- Another severe asthma treatment is attempting insurance reimbursement in Korea. According to industry sources, AstraZeneca is undergoing the reimbursement process for its monoclonal antibody for asthma, Fasenra (benralizumab). Other biological drugs including GSK’s ‘Nucala (mepolizumab),’ and Teva-Handok’s ‘Cinqair (reslizumab)’ hav
- Company
- Asthma treatment Cinqair attempts reimb again in Korea
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- The asthma treatment Cinqair for asthma is again attempting reimbursement listing in Korea. According to industry sources, Teva-Handok has recently submitted an application for the reimbursement listing of its interleukin-5 antagonist monoclonal antibody Cinqair (reslizumab). Following Cinqair’s steps, other biological drugs for asthma i
- Company
- Verzenio expects to address the unmet demand
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- Expectations are high for securing early breast cancer indications for Verzenio, a breast cancer treatment with CDK4/600 inhibition mechanism. Lilly Korea held a press conference on the 14th to commemorate the expansion of permission for early breast cancer indications at high risk of recurrence of the anticancer drug Verzenio. Verzenio obta
- Company
- Samsung Epis's Soliris biosimilar bioequivalent to original
- by Dec 14, 2022 05:56am
- Study results that show Samsung Bioepis’s Soliris biosimilar is bioequivalent to the original drug have been presented. On the 13th, the company announced that its biosimilar, SB12 has demonstrated equal effect to its original drug Soliris at the American Society of Hematology (ASH) Annual Meeting that is being held in New Orleans.
- Company
- Champix supply interruption
- by Kim, Jin-Gu Dec 14, 2022 05:56am
- Jeil Pharmaceutical's Nico Chams has dominated the market for anti-smoking treatment aids with Varenicline ingredients. Analysts say that while sales of major products, including Pfizer Champix, were suspended due to the detection of impurities in NNV components in September last year, it succeeded in digging into the gap and raising its influen
- Company
- 2022 Pharmaceutical Industry Advertising Target Call Members
- by Dec 14, 2022 05:56am
- Daewon Pharmaceutical's "Coldewon" and Sanofi's "Honey Jam Market for Those Who Can't Sleep" won the grand prize in the advertising and PR categories at the 2022 Korea Pharmaceutical Bio-Industry Advertising and PR Awards. Chong Kun Dang Benfobell won the grand prize in the "Special Award for Pharmacist Selection" category, which was decided
- Company
- Prolia's annual sales are expected to be 100 billion won
- by Kim, Jin-Gu Dec 14, 2022 05:56am
- Amgen's Prolia, which dominated the osteoporosis treatment market, is further strengthening its dominance system. Sales are expected to surpass 100 billion won by the end of this year. Evenity, a generic for Prolia, is also rapidly increasing its sales. It has grown into the second-largest product in the osteoporosis treatment market in less
- Company
- Baxter ranks first in the 70 billion hemostatic market
- by Nho, Byung Chul Dec 13, 2022 06:07am
- In the 70 billion won-shaped hemostatic market, Baxter Floseal is likely to surpass 30 billion won in sales this year, and is expected to rank first for the third consecutive year. According to the drug distribution performance data, Baxter Flossal's sales reached 25.3 billion won and Hyundai Pharmaceutical's Tachosil's sales reached 12.5 bi
